Last updated on May 2019

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis


Brief description of study

Primary Objective:

To evaluate the efficacy of dupilumab monotherapy compared to placebo treatment in adult patients with moderate-to-severe atopic dermatitis (AD).

Secondary Objectives:

  • To evaluate the safety of dupilumab monotherapy compared to placebo treatment in adult patients with moderate-to-severe AD.
  • To evaluate the effect of dupilumab on improving patient reported outcomes (PROs).
  • To evaluate dupilumab immunogenicity.

Detailed Study Description

The maximum study duration will be 33 weeks per patient, including a screening period of up to 5 weeks, a 16-week randomized treatment period, and a 12-week follow-up period.

Clinical Study Identifier: NCT03912259

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.